Safety Study of TroVax Alone vs. TroVax Plus Interferon Alpha in Patients With Renal Cancer
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
Patients with metastatic renal cell cancer will be enrolled to receive either Trovax® alone
or Trovax® plus Interferon Alfa. The study will try to determine whether the use of Trovax®
will delay tumor progression.
Phase:
Phase 2
Details
Lead Sponsor:
The Methodist Hospital Research Institute The Methodist Hospital System